Shenzhen Salubris Pharmaceuticals Co Ltd (002294) — Net Asset Quality Index
Shenzhen Salubris Pharmaceuticals Co Ltd (002294) has a Net Asset Quality Index of 81.3% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥10.98 Billion minus total liabilities of CN¥2.05 Billion yields net assets of CN¥8.93 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See how many days can Shenzhen Salubris Pharmaceuticals Co Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shenzhen Salubris Pharmaceuticals Co Ltd Net Asset Quality Index Over Time (2006–2024)
This chart shows how Shenzhen Salubris Pharmaceuticals Co Ltd's Net Asset Quality Index has evolved across 19 annual periods from 2006 to 2024. As of September 2025, the index stands at 81.3%, representing net assets of CN¥8.93 Billion against total assets of CN¥10.98 Billion CNY. Explore cash efficiency ratio of Shenzhen Salubris Pharmaceuticals Co Ltd to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
The table below presents the year-by-year Net Asset Quality Index for Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024, covering 19 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Shenzhen Salubris Pharmaceuticals Co Ltd stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 83.6% | CN¥8.75 Billion | CN¥10.47 Billion | CN¥1.71 Billion | ▼ -2.1 pp |
| 2023 | 85.7% | CN¥8.06 Billion | CN¥9.40 Billion | CN¥1.34 Billion | ▲ +4.0 pp |
| 2022 | 81.8% | CN¥7.98 Billion | CN¥9.76 Billion | CN¥1.78 Billion | ▼ -5.3 pp |
| 2021 | 87.0% | CN¥8.05 Billion | CN¥9.24 Billion | CN¥1.20 Billion | ▲ +6.2 pp |
| 2020 | 80.8% | CN¥5.59 Billion | CN¥6.92 Billion | CN¥1.33 Billion | ▼ -5.4 pp |
| 2019 | 86.2% | CN¥6.67 Billion | CN¥7.73 Billion | CN¥1.07 Billion | ▼ -0.7 pp |
| 2018 | 86.9% | CN¥6.87 Billion | CN¥7.90 Billion | CN¥1.03 Billion | ▼ -2.8 pp |
| 2017 | 89.7% | CN¥6.16 Billion | CN¥6.86 Billion | CN¥705.86 Million | ▲ +6.2 pp |
| 2016 | 83.6% | CN¥5.46 Billion | CN¥6.53 Billion | CN¥1.07 Billion | ▼ -3.6 pp |
| 2015 | 87.2% | CN¥4.70 Billion | CN¥5.39 Billion | CN¥691.25 Million | ▲ +5.1 pp |
| 2014 | 82.1% | CN¥3.79 Billion | CN¥4.62 Billion | CN¥827.95 Million | ▼ -4.0 pp |
| 2013 | 86.0% | CN¥3.13 Billion | CN¥3.64 Billion | CN¥508.36 Million | ▼ -1.4 pp |
| 2012 | 87.5% | CN¥2.61 Billion | CN¥2.98 Billion | CN¥374.02 Million | ▲ +0.2 pp |
| 2011 | 87.3% | CN¥2.13 Billion | CN¥2.45 Billion | CN¥310.52 Million | ▲ +1.5 pp |
| 2010 | 85.8% | CN¥1.87 Billion | CN¥2.17 Billion | CN¥309.50 Million | ▼ -5.8 pp |
| 2009 | 91.6% | CN¥1.62 Billion | CN¥1.77 Billion | CN¥148.59 Million | ▲ +27.3 pp |
| 2008 | 64.3% | CN¥262.90 Million | CN¥408.60 Million | CN¥145.70 Million | ▲ +7.3 pp |
| 2007 | 57.0% | CN¥145.96 Million | CN¥255.94 Million | CN¥109.98 Million | ▼ -10.1 pp |
| 2006 | 67.1% | CN¥106.48 Million | CN¥158.66 Million | CN¥52.19 Million | — |